HOME >> MEDICINE >> NEWS
VELCADE (Bortezomib) receives European marketing authorisation

Brussels, Belgium, {27 April 2004} Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced that the European Commission has issued a positive decision for VELCADE, a new treatment for multiple myeloma, a form of blood cancer. The novel drug is indicated to treat multiple myeloma patients who have received at least two prior therapies and demonstrated disease progression on their last therapy.

VELCADE is a completely new approach to treating multiple myeloma that acts on a unique target in cells called the proteasome.

Multiple myeloma is the second most common blood cancer, representing approximately one percent of all cancers and two percent of all cancer deaths. Worldwide in 2000, there were 73,943 cases of multiple myeloma and 57,370 deaths. In Europe there were approximately 19,000 cases in 2000 and just under 15,000 deaths (1). Only 30 percent of multiple myeloma patients survive longer than five years (2).

"The approval of VELCADE by the European Agency for the Evaluation of Medicinal Products (EMEA) represents a breakthrough in our continued battle against multiple myeloma" said Professor Mario Boccadoro, Professor of Hematology, Director of the Section of Hematology, University of Torino, Italy. "With its new and unique mechanism of action, VELCADE represents a new treatment option for patients".

Clinical results from a phase II study have shown that VELCADE can slow, reverse or halt progression of disease in patients who failed on two or more treatments, potentially helping patients live longer. In a study of 202 patients with relapsed and refractory multiple myeloma and who progressed after initial treatments, 35% responded to VELCADE and 10% had a complete remission. This pivotal study was the basis for an accelerated review of VELCADE by U.S. Food and Drug Administration (FDA) and approval within four months of the New Drug Application submission on 13 May 2003.

"We are deli
'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004


Page: 1 2 3

Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
(Date:11/27/2014)... The American Society for Clinical Pathology (ASCP) ... in honor of World AIDS Day 2014. On Nov. 25, ... cure.” icon and infographic designed to generate public awareness about ... HIV. , ASCP has asked members to replace their Facebook, ... Get Tested. Find a cure.” icon and share the accompanying ...
(Date:11/27/2014)... Luciana Lagana and her husband ... a feature film that received 9 awards at the 2014 ... cast. It is also an official selection of the 2014 ... successful cinematic career for James Noel, a young filmmaker who ... experimental mystery, filmed in glorious black and white, watching Omadox ...
(Date:11/27/2014)... An inventor from Buffalo, N.Y., knows that many ... she wants to lessen its impact. "After showering and ... there needed to be a way to maintain freshness ... and producible in design variations, the End Scentuous Body ... the day. It avoids bad odors, as well as ...
(Date:11/27/2014)... WEDNESDAY, Nov. 26, 2014 (HealthDay News) -- Most babies ... a cold, the U.S. Food and Drug Administration says. ... be given to children younger than 2 because they ... agency warned. American adults average about three colds ... children get a cold, parents might want to give ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 The founders of ... stylish, comfortable and high functioning compression socks, are proud to ... socks use an innovative Gradient Pressure (TM) knitting technology that ... , VIM & VIGR’s commitment to adding flair and style ... just functional recently caught the eye of a writer at ...
Breaking Medicine News(10 mins):Health News:ASCP Launches Social Media Campaign in Honor of World AIDS Day 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 2Health News:Luciana Lagana and Gregory Graham Join the Award-Winning Cast of the Black-and-White Experimental Mystery Feature Film Omadox. 3Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2
(Date:11/27/2014)... , Nov. 27, 2014 ... to Academic Research - JIN Co., Ltd. will ... a market price of 500,000 yen or $5,000 (without tax ... software). The "ACADEMIC PACK" is a dedicated solution of "JINS ... capture and analyze deep data* generated by electrooculography and six-axis ...
(Date:11/26/2014)... -- Cohen, Placitella & Roth, PC is investigating potential ... Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... 2011 through November 2, 2014 ("Class Period").  The ... officers and directors publically disseminated materially false and/or ... 20(a) of the Securities Exchange Act of 1934 ...
(Date:11/26/2014)... Md. , Nov. 26, 2014  Over 100 ... of those suffer from this pain daily. Chronic and ... of pain management is born to fulfill the need ... all types of pain. On October 28th, ... the Cumberland, Maryland community.  This ...
Breaking Medicine Technology:JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 2JIN to Launch JINS MEME ACADEMIC PACK in Late April 2015 3Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3New Pain Management Center Opens in Cumberland, Md. 2
Cached News: